Search
Anisotropine methylbromide
go.drugbank.com/drugs/DB00517ApprovedIts use as treatment adjunct in peptic ulcer has been replaced by the use of more effective agents.
Pyridoxal phosphate
go.drugbank.com/drugs/DB00114ApprovedInvestigationalNutraceuticalThis is the active form of vitamin B6 serving as a coenzyme for synthesis of amino acids, neurotransmitters (serotonin, norepinephrine), sphingolipids, aminolevulinic acid.
Cloxazolam
go.drugbank.com/drugs/DB01553ExperimentalAs well, it has also been studied in Japan in doses of 15-30mg/day as an adjunct in the treatment of intractable epilepsy, for which it has demonstrated effectiveness. … Although less commonly noted, it has also been reported as clinically effective in the treatment of depression, schizophrenia, and neurosis.
Simoctocog alfa
go.drugbank.com/drugs/DB09108ApprovedAs patients with haemophilia A are predisposed to episodes of recurrent bleeding [L1115], simoctocog alfa can be administered for the treatment or prevention of bleeding such as prior to surgical procedures … It is an antihemorrhagic agent used as a replacement therapy in individuals with Haemophilia A who lack the factor VIII in the intrinsic pathway of blood coagulation system.
Dilmapimod
go.drugbank.com/drugs/DB12140InvestigationalDilmapimod (SB-681323) is a p38 MAP-kinase inhibitor that has potential uses in inflammatory conditions such as RA (Rheumatoid Arthritis). … Methotrexate (common treatment for RA patients) also has potential liver toxicity.}
Resorcinol
go.drugbank.com/drugs/DB11085ApprovedInvestigationalIt is used as an antiseptic and disinfectant in topical pharmaceutical products in the treatment of skin disorders and infections such as acne, seborrheic dermatitis, eczema, psoriasis, corns, calluses … Although it is primarily indicated for use as a topical application, resorcinol also possesses a well-documented anti-thyroidal activity that is generally not relied upon for any kind of formal therapeutic
Relacorilant
go.drugbank.com/drugs/DB14976ApprovedInvestigationalOriginally investigated to manage the metabolic and endocrinologic complications of hypercortisolism, such as Cushing’s syndrome, its clinical utility has pivoted toward oncology as a potent sensitizing … [L56089] Relacorilant was approved by the US FDA on March 25, 2026, for use in combination with [paclitaxel] in patients with certain platinum-resistant cancers.[L56093,L56089]
Lapatinib
go.drugbank.com/drugs/DB01259ApprovedInvestigationalLapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. … It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine.
Acetohydroxamic acid
go.drugbank.com/drugs/DB00551ApprovedInvestigationalIn the urine, it acts as an antagonist of the bacterial enzyme urease. Acetohydroxamic Acid has no direct antimicrobial action and does not acidify urine directly.
Berdazimer
go.drugbank.com/drugs/DB18712Approved[A262960] Berdazimer was previously investigated as a potential treatment for molluscum contagiosum, a viral cutaneous infection mainly affecting children, sexually active adults, and immunocompromised … [A262965] Previously, the first line treatment for molluscum contagiosum was surgical excision, although it poses challenges such as repeated doctor visits, post-surgical scarring and skin discoloration